A Real-World, Prospective, Observational Study to Evaluate the Safety and Effectiveness of Rivaroxaban (Xarelto) for Prevention of Stroke and Systemic Embolism in Indian Patients With Non-valvular Atrial Fibrillation (NVAF)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 10 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rivaroxaban (Primary)
Indications Embolism; Stroke; Thromboembolism; Transient ischaemic attacks
Focus Adverse reactions
Acronyms XARIN
Sponsors Bayer; Bayer Zydus Pharma

Most Recent Events

08 Jan 2025 Status changed from active, no longer recruiting to completed.
10 Dec 2024 Planned End Date changed from 29 Nov 2024 to 16 Dec 2024.
12 Nov 2024 Planned End Date changed from 31 Oct 2024 to 29 Nov 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight